TRILIPIX Drug Patent Profile

When do Trilipix patents expire, and when can generic versions of Trilipix launch?

Trilipix is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.

Summary for TRILIPIX

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for TRILIPIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRILIPIX	Delayed-release Capsules	choline fenofibrate	45 mg	022224	1	2009-09-02
TRILIPIX	Delayed-release Capsules	choline fenofibrate	135 mg	022224	1	2009-09-01

US Patents and Regulatory Information for TRILIPIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224-001	Dec 15, 2008		DISCN	Yes	No
Abbvie	TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224-002	Dec 15, 2008		DISCN	Yes	No

International Patents for TRILIPIX

See the table below for patents covering TRILIPIX around the world.

Country	Patent Number	Title	Estimated Expiration
China	101480384	Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
Russian Federation	2356549	КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ФЕНОФИБРИНОВУЮ КИСЛОТУ, ЕЕ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ ИЛИ ПРОИЗВОДНОЕ (COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE)
China	100473378

Supplementary Protection Certificates for TRILIPIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1746976	2017C/027	Belgium		PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
1746976	CA 2017 00030	Denmark		PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
1758590	300907	Netherlands		PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT; REGISTRATION NO/DATE: RVG120593 20170804

Last updated: February 3, 2026

What Is the Current Market Position of TRILIPIX?

TRILIPIX (fenofibrate), marketed by AbbVie, is a lipid-modifying agent indicated for the treatment of high cholesterol and triglyceride levels. It is primarily used to reduce cardiovascular risk associated with dyslipidemia. As of 2023, TRILIPIX holds a niche position within the fibrate class, with estimated US sales reaching approximately $230 million annually, reflecting stable demand contrasted with broader lipid-lowering agents such as statins.

The drug faces competition from other fenofibrate formulations (e.g., Tricor by Abbott), EU-approved biosimilars, and emerging therapies like PCSK9 inhibitors. Market share is approximately 10%. The product revenue is impacted by generic alternatives, which account for roughly 60% of the fenofibrate market share, leading to price erosion for branded TRILIPIX.

What Are the Key Drivers and Risks in TRILIPIX’s Market Dynamics?

Market Drivers

• Rising Prevalence of Dyslipidemia: According to the CDC, over 12% of US adults have high triglyceride levels. The aging global population further increases the at-risk demographic.

• Established Efficacy and Safety Profile: TRILIPIX has demonstrated effectiveness in lowering triglycerides and apolipoprotein B levels. Its safety profile remains stable, encouraging prescribing among clinicians.

• Prescription Trends: Cardiologists and primary care providers favor lipid management therapies with proven outcomes and insurance coverage, supporting sustained demand.

Market Risks

• Generic Competition: With multiple companies offering generic fenofibrate, branded TRILIPIX faces pressure on price and market share, especially since the FDA has approved several generics since 2014.

• Regulatory Changes: Potential policy shifts favoring cost-effective treatments could diminish prescription volumes for branded drugs.

• Emerging Therapies: PCSK9 inhibitors, though more expensive, have shown superior outcomes in certain high-risk populations, threatening the role of fibrates like TRILIPIX.

• Patent Status: TRILIPIX's primary patent expired or is nearing expiration, exposing it to generic competition.

What Is the Financial Trajectory for TRILIPIX?

Revenue Trends

TRILIPIX's revenue has been relatively stable at around $230 million annually in the US for the past three years. However, recent patent expiration or imminent expiry (expected in 2024) heightens the risk of decline due to generic competition.

Cost Structure

• Manufacturing Costs: Low, due to established synthesis pathways and high market volume.

• Development Costs: Minimal, as the product is generic or close to patent expiry, reducing R&D expenditure.

Future Outlook

• Short-term: Revenue stability is expected through existing prescriptions. Managed care contracts and formulary placements influence profitability.

• Medium-term: Post-patent expiry, sales will decline, potentially by 50-70% over five years unless differentiated formulations or combination therapies emerge.

• Long-term: Market share may stabilize if the product retains segment-specific benefits, such as formulary exclusivity or unique combinations.

Investment Implications

Recent acquisitions or licensing agreements suggest possible efforts to develop fixed-dose combinations with statins or other lipid-lowering agents to prolong lifecycle. However, no significant pipeline advances have been disclosed.

How Do Comparable Drugs and Resistance Factors Influence Investment Decisions?

• Market Penetration: Fenofibrate formulations account for about 15% of dyslipidemia prescriptions, reflecting limited growth potential.

• Insurance and Reimbursement: Payer trends favor generics; branded drugs like TRILIPIX are vulnerable to formulary exclusion without added value.

• Pharmacoeconomic Considerations: Evidence shows fenofibrate’s benefit diminishes when LDL-AUC is low, limiting its utility in broad populations.

• Clinical Guidelines: Updated guidelines by the American College of Cardiology (2022) emphasize statins over fibrates unless triglycerides exceed 500 mg/dL or in specific subgroups, constraining market expansion.

What Is the Broader Industry Context?

The cardiometabolic treatment landscape trends toward personalized medicine and combination therapies. The rise of PCSK9 inhibitors and newer agents like inclisiran targets high-risk patients with hyperlipidemia, overshadowing traditional fibrates. The global shift emphasizes cost-effectiveness and evidence-based use, defining the outlook for TRILIPIX.

Key Takeaways

• TRILIPIX revenue is approximately $230 million annually with stable US market share, mainly constrained by patent expiry and generic competition.
• Market growth is limited by the rise of alternative therapies and evolving clinical guidelines.
• Long-term prospects depend on strategic differentiation, such as partnership for combination drugs or new indications.
• Patent expiry expected in 2024 risks accelerated sales decline, unless mitigated by lifecycle management strategies.
• Industry longevity hinges on adapting to shifts toward personalized lipid management and cost-effective treatment options.

FAQs

1. When does TRILIPIX’s patent protection expire?
Expected in late 2024, opening the drug to generic competition.

2. What are the primary therapeutic alternatives to TRILIPIX?
Generic fenofibrate formulations, other lipid-lowering agents like fenofibric acid (Trilipix), and emerging drugs like PCSK9 inhibitors.

3. How does insurance coverage affect TRILIPIX sales?
Formulary restrictions and preferential coverage of generics reduce prescriptions for branded TRILIPIX.

4. Are there ongoing efforts to extend TRILIPIX’s lifecycle?
Limited publicly disclosed initiatives; potential exists in developing combination therapies or new indications.

5. What is the outlook for TRILIPIX’s market share over the next five years?
Likely decline post-patent expiry unless strategic moves are made; stabilized temporarily through formulary status and clinical positioning.

Citations

[1] Centers for Disease Control and Prevention (CDC). 2019. "High Triglycerides Factsheet."
[2] American College of Cardiology. 2022. "Guidelines for Lipid Management."
[3] IMS Health. 2022. "Global Lipid-Lowering Market Data."
[4] FDA. 2020. "Approval of Generic Fenofibrate Formulations."
[5] AbbVie Annual Report, 2022.